Loading
Tryptophan and Brain Disorders / Intensive Care Unit Cognitive Disorders / Dementia and Cognitive Impairment Research · Journal article
Frontiers in Psychiatry · September 4, 2026
A consensus or society position rather than new primary data.
This is a narrative review integrating current evidence on the pathophysiology, clinical management, and emerging precision medicine approaches to late-life mental disorders (late-life depression, anxiety, BPSD). It synthesizes findings from systematic reviews and meta-analyses on topics including caregiver burden as a predictor of institutionalization, pharmacological and psychotherapeutic strategies, and integrated care models, while identifying critical gaps such as underrepresentation of older adults in trials and pervasive polypharmacy.
Narrative review. Older adults with late-life mental disorders (late-life depression, anxiety, behavioral and psychological symptoms of dementia).
Multiple systematic reviews and meta-analyses consistently identify caregiver burden and distress as significant predictors of nursing home admission, with carer stress sometimes the single determining factor for institutionalization Integrated care models (e.g., Collaborative Care Model) demonstrate superior outcomes over fragmented care Pathophysiological mechanisms include inflammaging, cerebral small vessel disease, and senescence of monoaminergic systems that collectively reduce neural resilience
Critical gaps remain including underrepresentation of older adults in clinical trials and pervasive polypharmacy
Clinicians should integrate caregiver well-being into routine clinical assessment, adopt tailored, multidisciplinary approaches balancing pharmacological and psychotherapeutic interventions with careful attention to age-related pharmacokinetic changes, and consider integrated care models over fragmented approaches. The review identifies emerging precision medicine targets (ketamine, biomarker-guided anti-inflammatory agents) and highlights the need for culturally equitable care.
A comprehensive narrative review synthesizing evidence on geriatric mental disorder pathophysiology, management, and emerging approaches; provides clinical roadmap rather than new primary evidence.
As stated by the source record.
Clinicians should integrate caregiver well-being into routine clinical assessment, adopt tailored, multidisciplinary approaches balancing pharmacological and psychotherapeutic interventions with careful attention to age-related pharmacokinetic changes, and consider integrated care models over fragmented approaches. The review identifies emerging precision medicine targets (ketamine, biomarker-guided anti-inflammatory agents) and highlights the need for culturally equitable care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The global aging demographic has precipitated a surge in late-life mental disorders (LMDs)—including late-life depression (LLD), anxiety, and behavioral and psychological symptoms of dementia (BPSD)—posing critical public health challenges. This review synthesizes current evidence on the unique pathophysiology, clinical management, and emerging frontiers of geriatric mental health, emphasizing the interplay of neurobiological aging, multimorbidity, and psychosocial stressors. Key pathophysiological mechanisms include “inflammaging” (microglial overactivation), cerebral small vessel disease (CSVD), and senescence of monoaminergic systems, which collectively reduce neural resilience and complicate diagnosis. Clinical challenges—such as atypical symptom presentation (e.g., somatic masking of depression), polypharmacy risks, and diagnostic ambiguity between LLD and pseudodementia—necessitate tailored interventions. Notably, caregiver burden represents an independent predictor of patient institutionalization. Multiple systematic reviews and meta-analyses have consistently identified caregiver burden and distress as significant predictors of nursing home admission, with carer stress sometimes serving as the single determining factor for this transition. This underscores the critical need to integrate caregiver well-being into routine clinical assessment. Pharmacological strategies prioritize SSRIs/SNRIs but require cautious dosing due to age-related pharmacokinetic alterations (e.g., reduced renal clearance) and cardiovascular/metabolic risks. Emerging targets (e.g., ketamine for treatment-resistant LLD, anti-inflammatory agents guided by biomarker profiling) highlight a shift toward precision. Psychotherapeutic adaptations—including modified cognitive behavioral therapy (CBT), problem-solving therapy (PST), and life review therapy—address cognitive and psychosocial needs, while integrated care models (e.g., Collaborative Care Model [CoCM]) demonstrate superior outcomes over fragmented care. Lifestyle interventions (exercise) and neuromodulation (rTMS) further expand treatment options. Critical gaps remain, including underrepresentation of older adults in clinical trials and pervasive polypharmacy. Future directions emphasize pharmacogenomics, AI-driven early detection, and culturally equitable care to advance precision psychiatry for LMDs. This synthesis provides clinicians and researchers with a roadmap to navigate the complexities of geriatric mental health, advocating for multidisciplinary, patient-centered approaches to improve outcomes in aging populations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.